Cytokinetics Inc vs Jones Lang LaSalle Inc — how do they compare? Cytokinetics Inc trades at $77.39 (market cap $10.63B), while Jones Lang LaSalle Inc trades at $364.99 (market cap $16.72B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| CYTK | JLL | |
|---|---|---|
Market Cap | $10.63B | $16.72B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $373.24 |
52-Week Low | $34.31 | $280.16 |
Enterprise Value | $10.74B | $19.48B |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →